The FDA's April 2026 removal of BPC-157 from Category 2 safety-risk restrictions and its subsequent July 23-24 Pharmacy Compounding Advisory Committee review have shaped current trader views on placement in Category 1 for 503A compounding eligibility. The panel voted narrowly (8-6 with one abstention) to recommend the peptide despite FDA staff opposition, citing potential uses such as tissue repair. Full Category 1 status, however, requires formal notice-and-comment rulemaking that typically spans eight to twelve months after any recommendation. No final agency decision has occurred as of mid-August 2026. Key variables include the pace of the rulemaking process, any additional agency guidance on 503B facilities, and broader policy signals affecting bulk drug substance nominations.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · DiperbaruiBARU
Aug 31, 2026
August 31, 2026
14%
December 31, 2026
54%
$2,598 Vol.
August 31, 2026
$892 Vol.
14%
December 31, 2026
$1,706 Vol.
54%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's April 2026 removal of BPC-157 from Category 2 safety-risk restrictions and its subsequent July 23-24 Pharmacy Compounding Advisory Committee review have shaped current trader views on placement in Category 1 for 503A compounding eligibility. The panel voted narrowly (8-6 with one abstention) to recommend the peptide despite FDA staff opposition, citing potential uses such as tissue repair. Full Category 1 status, however, requires formal notice-and-comment rulemaking that typically spans eight to twelve months after any recommendation. No final agency decision has occurred as of mid-August 2026. Key variables include the pace of the rulemaking process, any additional agency guidance on 503B facilities, and broader policy signals affecting bulk drug substance nominations.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Pasar Dibuka: Jun 22, 2026, 10:10 PM ET
Volume
$2,598Tanggal Berakhir
Dec 31, 2026Pasar Dibuka
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's April 2026 removal of BPC-157 from Category 2 safety-risk restrictions and its subsequent July 23-24 Pharmacy Compounding Advisory Committee review have shaped current trader views on placement in Category 1 for 503A compounding eligibility. The panel voted narrowly (8-6 with one abstention) to recommend the peptide despite FDA staff opposition, citing potential uses such as tissue repair. Full Category 1 status, however, requires formal notice-and-comment rulemaking that typically spans eight to twelve months after any recommendation. No final agency decision has occurred as of mid-August 2026. Key variables include the pace of the rulemaking process, any additional agency guidance on 503B facilities, and broader policy signals affecting bulk drug substance nominations.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$2,598Tanggal Berakhir
Dec 31, 2026Pasar Dibuka
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA's April 2026 removal of BPC-157 from Category 2 safety-risk restrictions and its subsequent July 23-24 Pharmacy Compounding Advisory Committee review have shaped current trader views on placement in Category 1 for 503A compounding eligibility. The panel voted narrowly (8-6 with one abstention) to recommend the peptide despite FDA staff opposition, citing potential uses such as tissue repair. Full Category 1 status, however, requires formal notice-and-comment rulemaking that typically spans eight to twelve months after any recommendation. No final agency decision has occurred as of mid-August 2026. Key variables include the pace of the rulemaking process, any additional agency guidance on 503B facilities, and broader policy signals affecting bulk drug substance nominations.
Ringkasan eksperimental yang dihasilkan AI dengan referensi data Polymarket. Ini bukan saran trading dan tidak berperan dalam bagaimana pasar ini diselesaikan. · Diperbarui
Hati-hati dengan link eksternal.
Hati-hati dengan link eksternal.
Pertanyaan yang Sering Diajukan